Comprehensive Study Notes on Iron Overload and Clinical Management of Iron Overload
Overview of Iron Overload
- Definition: Iron overload, also known as Hemochromatosis, is a medical condition characterized by the accumulation of excessive iron within body tissues. This accumulation primarily affects the liver, heart, and pancreas, potentially leading to organ failure.
- Categorization:
- Primary (Hereditary): This form stems from genetic factors that cause the body to absorb too much iron.
- Secondary: This form arises from external factors or underlying conditions such as repeated blood transfusions or chronic liver disease.
- General Pathophysiology:
- Excessive accumulation eventually leads to tissue damage.
- Parenchymal iron overload often occurs due to excessive intestinal absorption.
- Parenterally administered iron (e.g., via transfusions) is initially taken up by macrophages in senescent red cells.
- There is no absolute distinction between these sources, as macrophage iron is slowly released to transferrin and subsequently taken up by parenchymal cells.
- Severity Threshold: Severe iron overload is arbitrarily defined as an excess of more than 5g. This level is typically confined to genetic hemochromatosis, iron-loading anemias, and sub-Saharan African dietary iron overload.
Case Scenario: 18-Year-Old Thalassemic Patient
- Clinical Presentation:
- Age: 18 years old.
- Condition: Known thalassaemic.
- Symptoms: Abdominal pain, joint pain, shortness of breath, dizziness, and headache.
- Past Medical History (PMH): Regular blood transfusions twice per month.
- Physical Examination (O/E): Pale, jaundiced, distended abdomen. Mild tenderness on the Right metacarpophalangeal (MCP) joints.
- Analysis Questions:
- Question 1: Explain the patient’s clinical condition.
- Question 2: What are the reasons for his condition?
- Question 3: What tests will you request for him and explain why for each?
- Question 4: What are the expected complications specific for his condition?
Causes and Classification of Iron Overload
Severe Iron Overload (>5g excess)
- Excess Iron Absorption:
- Hereditary haemochromatosis.
- Massive ineffective erythropoiesis (e.g., β-thalassaemia intermedia, sideroblastic anaemia, congenital dyserythropoietic anaemia).
- Increased Iron Intake:
- Sub-Saharan dietary iron overload (often combined with a genetic determinant of increased absorption).
- Excess Parenteral Iron Therapy:
- Repeated red cell transfusions for congenital anaemias (e.g., β-thalassaemia major, sickle cell anaemia, red cell aplasia).
- Acquired refractory anaemias (e.g., myelodysplasia, aplastic anaemia).
Modest Iron Overload (<5g excess)
- Chronic liver disease (e.g., alcoholic cirrhosis).
- Porphyria cutanea tarda.
- Rare genetic disorders (e.g., atransferrinaemia, acaeruloplasminaemia, DMT1 mutations).
Focal Iron Overload
- Pulmonary haemorrhage or idiopathic pulmonary haemosiderosis.
- Chronic haemoglobinuria (e.g., paroxysmal nocturnal haemoglobinuria).
Genetic Haemochromatosis Types
- Type 1 (HFE-associated):
- Gene: HFE (atypical MHC class I-like gene on chromosome 6).
- Inheritance: Autosomal Recessive (AR).
- Severity: Highly variable.
- Incidence: Common, particularly in Northern European populations.
- Mutations: 90% are homozygous for the Cys282Tyr (C282Y) mutation (G→A substitution at nucleotide 845). A second variant is His63Asp (H63D).
- Type 2 (Juvenile Haemochromatosis):
- Gene: Hemojuvelin (HFE2) or Hepcidin (HAMP).
- Inheritance: Autosomal Recessive (AR).
- Severity: Severe; onset often in teenagers or individuals in their early 20s (as low as age 5).
- Incidence: Rare.
- Type 3:
- Gene: Transferrin receptor 2 (TFR2).
- Inheritance: Autosomal Recessive (AR).
- Severity: Variable.
- Incidence: Rare.
- Type 4 (Ferroportin Disease):
- Gene: Ferroportin 1 (SLC11A3).
- Inheritance: Autosomal Dominant (AD).
- Severity: Variable.
- Incidence: Rare.
Pathophysiology of Type 1 Haemochromatosis
- Nature of Defect: Deficient hepcidin production leads to unregulated intestinal iron absorption and increased mucosal iron transfer to plasma.
- Hepcidin Function: Hepcidin is a negative regulator of iron. It binds to ferroportin, causing its internalization and lysosomal degradation.
- Impact of Low Hepcidin:
- Upregulates ferroportin in the duodenal mucosa.
- Increases mucosal iron transfer to transferrin.
- Leaves duodenal cells iron deficient.
- Macrophages fail to retain iron, leading to low iron levels in macrophages and high serum iron in early stages.
- Modifiers of Phenotype:
- Full expression depends on dietary iron intake, blood loss (including menstruation and pregnancy), and modifying genetic factors.
Clinical Presentation and Complications
- Liver: Cirrhosis. Hepatocellular carcinoma develops in 25% of cases with established cirrhosis. Hepatic enlargement may cause abdominal pain.
- Endocrine:
- Diabetes mellitus (from iron deposition in pancreatic islets).
- Hypogonadism (gonadal failure).
- Hypothyroidism and hypoparathyroidism (common in poorly chelated patients).
- Growth failure due to reduced growth hormone secretion or insulin-like growth factor deficiency.
- Musculoskeletal:
- Arthritis, particularly affecting the second and third metacarpophalangeal joints.
- Destructive arthropathy of hip and knee joints (10% of patients).
- Chondrocalcinosis with pyrophosphate deposition.
- Osteoporosis (detected by Dexa scan).
- Cardiovascular: Cardiomyopathy and heart failure.
- Dermatological: Slate-grey skin pigmentation caused by excess melanin deposition.
- General: Fatigue.
Diagnosis and Monitoring
Iron Status Markers
- Transferrin Saturation: Essential for early detection. A value of >45% indicates iron accumulation. It may be depressed during infection or inflammation.
- Serum Ferritin: Rising values suggest overload. Thresholds are >200μg/L for women and >300μg/L for men. Values above 1000μg/L in C282Y homozygotes make liver biopsy essential to assess damage.
Liver Assessment
- Liver Biopsy:
- Used to assess liver structure and iron burden (histologically via Perls stain and chemically).
- Liver Iron Concentration (LIC): Values >80μmol/g dry weight (4.5mg/g dry weight) indicate overload.
- Hepatic Iron Index: (μmoliron/gdryweight)/age in years.
- MRI (T2* Technique): A non-invasive method to measure liver and heart iron. It distinguishes between cardiac and liver iron deposition.
- SQUID (Superconducting Quantum Interface Device): Sensitive biosusceptometry based on the paramagnetic properties of hemosiderin and ferritin. It does not distinguish parenchymal from reticuloendothelial iron.
Family and Population Screening
- Family Testing: First-degree relatives should be tested via transferrin saturation, serum ferritin, and HFE genotyping.
- Population Screening: Currently considered unwarranted for the general population due to low clinical penetrance in C282Y homozygotes.
- Type 4a (Classic Ferroportin Disease):
- Phenotype similar to anemia of chronic disease.
- Iron accumulation predominantly in macrophages (Kupffer cells).
- Normal or low transferrin saturation.
- Caused by loss-of-function mutations preventing ferroportin from reaching the cell surface.
- Type 4b:
- Mutations occur in the hepcidin-binding site of ferroportin.
- Ferroportin is resistant to hepcidin, causing increased iron export to plasma.
- Phenotype similar to HFE haemochromatosis (parenchymal iron deposition).
- Neonatal Haemochromatosis: Recognized at birth or in utero; characterized by irreversible liver failure. Likely immunological pathogenesis (maternal alloantibodies).
- African Iron Overload (Bantu Siderosis): Combination of dietary iron (traditional beer) and an unknown susceptibility gene. Associated with hepatic fibrosis, diabetes, scurvy, and osteoporosis.
- Atransferrinaemia: Rare recessive disorder causing severe hypochromic anemia and non-transferrin-bound iron (NTBI) deposition.
- Acaeruloplasminaemia: Deficiency in ferroxidase activity. Presents with retinal degeneration, basal ganglia degeneration, and diabetes. Serum iron is low, but iron accumulates in the brain and organs.
- Hallervorden Spatz Syndrome (PKAN): Autosomal recessive neurodegeneration with brain iron accumulation. Caused by a pantothenate kinase gene defect.
- Neuroferritinopathy: Dominantly inherited late-onset basal ganglia disease. Ferritin light-chain (FTL) gene mutation.
- Friedreich Ataxia (FA): Mitochondrial iron overload and loss of iron-sulphur cluster-containing enzymes. Marked by sensory neuron loss and cardiomyopathy.
Iron Overload in Ineffective Erythropoiesis (IE)
- Mechanism: Failure of RBC production leads to suppression of hepcidin via signals like Erythroferrone (ERFE), GDF15, and TWSG1 released by dying erythroblasts.
- NTBI: When erythropoiesis cannot use iron, transferrin becomes saturated, leading to Non-Transferrin-Bound Iron (NTBI), which enters tissues in an unregulated manner.
- Conditions: Thalassemia, Myelodysplastic Syndrome (MDS), and Congenital Dyserythropoietic Anaemias (CDAs).
Acute Iron Poisoning
- Clinical Signs: Severe necrotizing gastritis/enteritis, metabolic acidosis, cardiovascular collapse, and liver damage.
- Treatment: Oral and parenteral Deferoxamine (DFX). Gastric lavage with 1% sodium bicarbonate may be used prior to instilling 5g of DFX into the stomach.